Association of serum prostate-specific antigen with Complete Blood Counts in patients with prostatic cancer

Abstract

Background: Prostate cancer is the second most common cancer and one of the most leadingcauses of death in men worldwide. The prostate-specific antigen (PSA) as a screening methodshowed that there has been a slight decrease in prostate cancer mortality. Effective biomarkers inscreening and diagnosis would be beneficial for avoiding unnecessary operations. The predictive andprognostic value of complete blood count (CBC) has been manifested by recent studies. We aimed todetermine the association of serum PSA with Complete blood counts in patients with prostate cancer.Method: The present study included 100 subjects, 50 patients diagnosed with new prostate cancerand 50 patients with prostate cancer. All the was undertaken in the central diagnostic laboratory atVIMS and RC. Blood samples were collected from all the subjects after taken permission from theinstitutional ethics committee and consent form. The haemoglobin, RBCs, MCV, MCHC, RDW will beanalysed by using laboratory standard methods (Beckman coulter LH-780) and The serum PSAlevels are estimated by commercially available kits based on enzyme-linked immunosorbent assay(ELISA). Results: In the present study found significantly elevated levels of a prostate specificantigen in both groups of prostatic cancer patients. The reduced levels of hemoglobin, red bloodcells, platelets, neutrophils were observed in prostatic cancer patients when compared to newlydiagnosed prostate cancer patients. The PSA levels were negatively correlated with total bloodcounts. Conclusion: This study suggests that the elevated levels of prostate specific antigen wereuseful for diagnosis and prognosis of prostatic cancers, along with the monitoring of complete bloodcount may be useful for the treatment of patients with prostatic cancers.